Minocycline topical gel - Foamix

Drug Profile

Minocycline topical gel - Foamix

Latest Information Update: 06 Jun 2014

Price : $50

At a glance

  • Originator Foamix
  • Class Amides; Antibacterials; Dimethylamines; Neuroprotectants; Small molecules; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Clinical Phase Unknown Age-related macular degeneration; Blepharitis; Chlamydial infections; Diabetic macular oedema; Glaucoma; Ophthalmic infections; Rosacea

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 03 Jun 2014 Foamix enters into a collaboration with the National Eye Institute to develop therapeutics for the treatment of geographic atrophy, a form of age-related macular degeneration
  • 28 Aug 2013 Minocycline topical gel - Foamix is available for licensing as of 28 Aug 2013. http://www.foamix.co.il/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top